Leyden Labs logo

Leyden Labs

Startups icon Seedtable Score 56 Startups icon Startups

2

Founding Rounds

2

Investors

$187.64m

Money raised

Overview

Leyden Labs, based in Amsterdam, specializes in producing medicines to safeguard against respiratory viruses. Their focus on this niche area is significant as current vaccines, masks, and antiviral treatments show limited efficacy against evolving viral threats. By potentially offering broader or more targeted protection, Leyden Labs could become a key player in the biotech and health technology sectors. Backed by major investors like GV and SoftBank Group, the company enjoys strong confidence in its business model and technological innovation. As the focus shifts from reactive to proactive measures, Leyden Labs' products could see substantial demand, solidifying their market position.

Investors (2)

SoftBank Group logo SoftBank Group

Climate Tech & Green Tech, Health Tech, Edtech, FinTech, Crypto & web3, ...

Details
GV logo GV

Climate Tech & Green Tech, Health Tech, Edtech, FinTech, Crypto & web3, ...

Details

View all investors.

Join 23,000+ founders, operators and investors.

Fonding

Fonding series

Funding Series Analysis

The company Leyden Labs has raised a total of $187.64m in funding over 2 rounds.

Key Insights:

  • Series B: $140m
  • Unknown: $47.64m
Leyden Labs logo
Leyden Labs Unknown (2021, $47M) $47.64m
Leyden Labs logo
Leyden Labs Series B (2022, $140M) $140m